Innovate Initiates its Dosing For P-III CeD LA 3001 Trial for Celiac Disease


  • The P-III study involves assessing of larazotide acetate as an adjuvant therapy vs PBO in patients with celiac disease who still experience symptoms despite being on a gluten-free diet
  • Innovate marks to be the first company in patient dosing in P-III celiac disease. Larazotide has met 1EPs in P-IIb efficacy clinical trial enrolling 342 patients and has also received FDA’s Fast Track Designation for Celiac Disease
  • Larazotide acetate, or INN-202 is oral therapy and a tight junction regulator targeted for restoring leaky or open junctions to a normal state administered TID prior the meal. Additionally, Larazotide is evaluated in ~600 subjects in clinical trials, demonstrated safety profile vs PBO for long-term chronic administration

Click here to read full press release/ article | Ref: Innovate Pharmaceuticals | Image: Behance